Memorial Sloan Kettering Cancer Center's updated Phase 1 results show 7 of 8 immune responders (87.5%) to BioNTech's personalized mRNA vaccine autogene cevumeran (BNT122) remain alive 4 to 6 years after pancreatic cancer surgery, principal investigator Dr. Vinod Balachandran reported. Only 2 of 8 non-responders survived, with a median survival of 3.4 years.
The 16-patient trial paired the vaccine with chemotherapy and an immunotherapy checkpoint inhibitor. Each vaccine was custom-designed in Germany from the patient's tumor genetics and delivered within nine weeks of surgery. Standard five-year survival for pancreatic cancer sits near 13%, according to the American Cancer Society.
Balachandran called the immune response "very potent" with "exceptional durability." BioNTech and Genentech, a member of the Roche Group, are now expanding the work into a larger Phase 2 study after MSK reaffirmed the data on April 19, 2026.